Moderna, Merck Skin Cancer Vaccine Cuts Risks of Death in Trial

Moderna Inc.'s experimental personalized cancer vaccine reduced the risk of relapse or death from melanoma when combined with Merck & Co.'s Keytruda in a mid-stage trial. The combination cut the death risk or recurrence of the skin cancer by 44%. cut The drugmakers want to move into final-stage studies next year. Moderna CEO Stephane Bancel speaks with Bloomberg's Guy Johnson and Alix Steel.
Follow Bloomberg for business news & analysis, up-to-the-minute market data, features, profiles and more: www.bloomberg.com
Connect with us on...
Twitter: / business
Facebook: / bloombergbusiness
Instagram: www.instagram....

[@jappiejojo777]

Fantastic. Congratulations

[@minionmememindset7889]

Lock this criminal up!!

[@hongry-life]

Is this the Merck of the Beast?

[@tomhaggerty8063]

Liars!

[@hongry-life]

Safe and effective.

[@anthonysalafia7017]

Just another money spinner by the big vacation companys

[@1ndigoch1ld81]

My Dad bragged about getting the Moderna vaccine. He didn’t get his booster because He died, and He didn’t have Covid.

[@R1GAMBLER]

*AVENGE HIM.*

[@eyalkarni3290]

How is it related? He also drank water and died

[@hongry-life]

It becomes all known now. Not a comfort for you, but truth will prevail.

[@adelereaodu]

About 16k cases in the UK a year, 9 out 10 is preventable. From a population of 67M? Why vaccine not medicine? This is only for the benefit of shareholders not populace.

[@TKGZONE]

$$$$$ 🤑💰💸

[@NotFinancialAdvice69]

🤣🤣🤣🤣

[@R1GAMBLER]

☝🏻 oh look, a criminal

[@eyalkarni3290]

A savior